Funding for this research was provided by:
Patient-Centered Outcomes Research Institute (PCS-2017C3-9252, PCS-2017C3-9252)
Received: 21 April 2021
Accepted: 29 May 2022
First Online: 20 June 2022
: This study was approved by the West Virginia University Institutional Review Board, protocol number 1812375609. Every participant will be required to provide informed consent prior to enrolling in the study.
: Not applicable.
: In the past 3 years, RCK has been a consultant for Datastat, Inc, Sage Pharmaceuticals, and Takeda. WRP consulted for CurAegis Technologies and received clinical trial support from Pfizer, Inc and Abbvie, Inc. AE and DR are employees of SilverCloud Health, developers of computerized psychological interventions for depression, anxiety, stress, sleep, resilience, and comorbid long-term conditions. In the past 3 years, JT has received research support from Otsuka. MWH has received funding from Insightec and has been a paid grand rounds speaker for Medtronic and Atrium Health. AAN serves on scientific advisory boards for Alkermes, Jazz Pharmaceuticals, Sage Pharmaceuticals, Otsuka, and Neuronetics; was a consultant for Acadia Pharmaceuticals, Esai, Myriad, Merck, Ginger, Protogenics, Neurogenics and Clexio; and also reports receiving honoraria from Sunovion and Neurostar.